Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Magli

Showing results (491-500 of 514) with videos related to

Pageof 52
Sort By:
European Urology Oncology|December 16, 2025
Prostate-specific Antigen Nadir and Time to Nadir Predict Recurrence in Postprostatectomy Patients Treated with Salvage Radiotherapy Without Androgen Deprivation TherapyFederico Mastroleo, Riccardo Villa, Mattia Zaffaroni, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 10, 2024
Worsening of 2-year patient-reported intestinal functionality after radiotherapy for prostate cancer including pelvic node irradiationGiuseppe Sanguineti, Maddalena Pavarini, Fernando Munoz, et al.
European Urology|June 24, 2023
European Association of Urology Biochemical Recurrence Risk Classification as a Decision Tool for Salvage Radiotherapy-A Multicenter StudyFelix Preisser, Raisa S Abrams-Pompe, Piter Jan Stelwagen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 4, 2025
Predictors of toxicities and oncological outcomes following postoperative ablative radiotherapy (POPART) for biochemical recurrenceFederica Ferrario, Ciro Franzese, Suela Vukcaj, et al.
World Journal of Urology|March 13, 2019
Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter studyLuca Triggiani, Rosario Mazzola, Stefano Maria Magrini, et al.
BJR Open|March 25, 2024
Stereotactic prostate radiotherapy with or without androgen deprivation therapy, study protocol for a phase III, multi-institutional randomized-controlled trialMarco Lorenzo Bonù, Alessandro Magli, Davide Tomasini, et al.
Cancer Research Communications|March 28, 2024
Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin TreatmentGiorgia Maroni, Indira Krishnan, Roberta Alfieri, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 25, 2025
Analysis of patients with locally advanced rectal cancer given neoadjuvant radiochemotherapy with or without RT dose intensification: A multicenter retrospective study - ATLANTIS part ILuca Nicosia, Marco Lorenzo Bonù, Ilaria Angelicone, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 19, 2025
Preclinical quality, safety, and efficacy of a CGMP iPSC-derived myogenic progenitor product for the treatment of muscular dystrophiesKarim Azzag, Alessandro Magli, James Kiley, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 19, 2024
Pelvic bone marrow dose-volume predictors of late lymphopenia following pelvic lymph node radiation therapy for prostate cancerMaddalena Pavarini, Lisa Alborghetti, Stefania Aimonetto, et al.
Pageof 52

Showing results (491-500 of 514) with videos related to

Sort By:
Pageof 52
European Urology Oncology|December 16, 2025
Prostate-specific Antigen Nadir and Time to Nadir Predict Recurrence in Postprostatectomy Patients Treated with Salvage Radiotherapy Without Androgen Deprivation TherapyFederico Mastroleo, Riccardo Villa, Mattia Zaffaroni, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 10, 2024
Worsening of 2-year patient-reported intestinal functionality after radiotherapy for prostate cancer including pelvic node irradiationGiuseppe Sanguineti, Maddalena Pavarini, Fernando Munoz, et al.
European Urology|June 24, 2023
European Association of Urology Biochemical Recurrence Risk Classification as a Decision Tool for Salvage Radiotherapy-A Multicenter StudyFelix Preisser, Raisa S Abrams-Pompe, Piter Jan Stelwagen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 4, 2025
Predictors of toxicities and oncological outcomes following postoperative ablative radiotherapy (POPART) for biochemical recurrenceFederica Ferrario, Ciro Franzese, Suela Vukcaj, et al.
World Journal of Urology|March 13, 2019
Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter studyLuca Triggiani, Rosario Mazzola, Stefano Maria Magrini, et al.
BJR Open|March 25, 2024
Stereotactic prostate radiotherapy with or without androgen deprivation therapy, study protocol for a phase III, multi-institutional randomized-controlled trialMarco Lorenzo Bonù, Alessandro Magli, Davide Tomasini, et al.
Cancer Research Communications|March 28, 2024
Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin TreatmentGiorgia Maroni, Indira Krishnan, Roberta Alfieri, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 25, 2025
Analysis of patients with locally advanced rectal cancer given neoadjuvant radiochemotherapy with or without RT dose intensification: A multicenter retrospective study - ATLANTIS part ILuca Nicosia, Marco Lorenzo Bonù, Ilaria Angelicone, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 19, 2025
Preclinical quality, safety, and efficacy of a CGMP iPSC-derived myogenic progenitor product for the treatment of muscular dystrophiesKarim Azzag, Alessandro Magli, James Kiley, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 19, 2024
Pelvic bone marrow dose-volume predictors of late lymphopenia following pelvic lymph node radiation therapy for prostate cancerMaddalena Pavarini, Lisa Alborghetti, Stefania Aimonetto, et al.
Pageof 52